Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g. capability of or availability for Diary Card completion, return for follow-up visits, availability for clinical follow-up throughout the study period).~* Written/ thumb printed informed consent obtained from the subject prior to performing any study specific procedure or written/ thumb printed informed consent obtained from the subject's parent(s)/ legally acceptable representative(s) (LAR\[s\]) and written/ thumb printed informed assent obtained from the subject, for minor subjects. This will only be applicable for countries where the legal age of majority is ≥ 21 years.~* A male or female aged 18 years of age or older at the time of Screening.~* Healthy subjects as per Investigator judgement, as established by medical history, clinical examination and haematology/ biochemistry laboratory parameters screening before entering into the study.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~* has practiced adequate contraception for 30 days prior to the Day 0 visit, and~* has a negative pregnancy test at the Day 0 visit, and~* has agreed to continue adequate contraception until 30 days after the Month 6 visit.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine during the period starting 30 days before the Day 0 visit, or planned use during the study period.~* Previous vaccination with an investigational EBOV or Marburg vaccine, or previous vaccination with a chimpanzee adenoviral vectored investigational vaccine.~* Known prior EBOV or SUDV disease.~* Travel to a country affected by the EBOV epidemic or direct contact with a person with EVD within 21 days prior to the Day 0 visit.~* History of any reaction or hypersensitivity (such as anaphylaxis, urticaria \[hives\], respiratory difficulty, angioedema, or abdominal pain) likely to be exacerbated by any component of the study vaccine.~* Planned administration/ administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after each vaccination visit.~* Serious acute or chronic illness determined by medical history and clinical examination including, but not limited to:~  * Clinically significant immunosuppressive or immunodeficient condition (e.g. clinical acquired immune deficiency syndrome \[AIDS\]).~ * Any clinically significant haematological (CBC, including differential count and platelet count) or biochemical (ALT, creatinine) laboratory abnormality.~ * Any chronic illness with recent signs of exacerbation, or imposing a change in the chronic treatment regimen, within 3 months prior to the Day 0 visit.~ * Any unstable chronic medical condition (e.g. uncontrolled asthma).~* Pregnant female.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group EBO-Z (Type: EXPERIMENTAL): The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
- Group Placebo/ EBO-Z (Type: PLACEBO_COMPARATOR): The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).